Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.37−0.39 (-5.03%)
Close on Nov 16, 2026Market cap $395.25MP/E –Yield –
Avalo Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Avalo Therapeutics's EV/EBITDA was 14.1× on Oct 31, 2018.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2018 | Oct 31, 2018 | 14.1× | +10.5 |
| 2017 | Dec 29, 2017 | 3.6× | – |
See a number that looks wrong?